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Purpose: A 2011 survey on the practice of intensity-modulated 
radiotherapy (IMRT) in the treatment of vulvar carcinoma 
originally highlighted areas of controversy and subsequently lead 
to the establishment of consensus recommendations for 
contouring and treatment in vulvar carcinoma. The present study 
aims to outline changes in practice over the last five years. 
Methods and Materials: Radiation oncologists with an expertise 
in gynaecological malignancies from a multi-national consortium 
(North America, Australia and Europe) were asked to complete a 
web based survey in 2011, then in 2016. Questions covered a 
wide range of issues in regards to staging, planning and IMRT 
treatment of vulvar cancer. Pearson’s chi-squared test was used 
to compare the two surveys. 
Results: Thirty-five radiation oncologists completed the survey 
in 2011, 24 in 2016. Half of the respondents were from the USA. 
An increase in the use of IMRT was reported. In 2011, 29% have 
never used IMRT in the management of vulvar cancer, compared 
to 4% in 2016, and 23% have treated more than 10 patients with 
IMRT in 2011, compared to 75% in 2016 (p = 0.006). PET-CT was 
used for staging by 69% of respondents in 2011 as compared to 
88% in 2016 (p = 0.09). There was also an increase in the use of 
MRI for planning purposes (p = 0.018) and more physicians now 
report replanning during the course of treatment (74% versus 
25%; p = 0.001). More respondents now use a higher total dose (≥ 
66 Gy) to the primary lesion (55% versus 41%; p = 0.312) although 
it did not reach statistical significance. There remains 
controversy on the total dose to deliver to involved lymph nodes. 
Similarly, there remains considerable variation in clinical target 
volume (CTV) definitions for different clinical scenarios as well 
as dose constraints for organs at risk (OAR). There is a trend of 
an increasing bone marrow contouring by radiation oncologists 
(47% versus 29%; p = 0.19), but there is still considerable 
discrepancy in the pelvic bones selected to represent ‘bone 
marrow’. Weekly cisplatin at 40 mg/m2 remains the most 
commonly used concurrent chemotherapy regimen. 
Conclusions: The use of IMRT for vulvar cancer has increased 
over the past five years. CTV definition and OAR dose constraints 
remain the biggest areas of controversy, highlighting the need 
for new consensus recommendations. 
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Purpose: Patients with left-sided breast cancer receiving 
radiotherapy (RT) are at increased risk of cardiac toxicity. 
Anatomic features that predict which breast patients would 
benefit from BH-RT for cardiac-sparing have been proposed. The 
purpose of this study is to evaluate the performance of a new 
metric in comparison to existing predictors in determining the 
need for BH-RT. 
Methods and Materials: In this single institution study, 50 
randomly selected left-breast cancer patients treated with BH-
RT were evaluated. Free-breathing and breath-hold images are 
both acquired during planning and the former set were used in 
this analysis. Target volumes and organs at risk were contoured 
using RTOG and consensus-based atlases. Using a cut-off of > 10 
cc V50% or mean heart dose (MHD) ≥1.7 Gy as selection criteria 
for BH-RT, a study by Lee et al. previously described the 
parasagittal heart contact with the chest wall length 
(HeartContact) as the most accurate predictor of benefiting from 
BH-RT use. We evaluated the performance of HeartContact 
versus two new candidate variables, measured as the lateral 
length between the left sternal edge to the beginning of lung 
parenchyma at the 1) fourth (Arch4) and 2) fifth costal arch 
(Arch5) levels. These three independent variables were 
compared with mean heart dose (MHD), V50% heart volume and 
left anterior descending coronary (LAD) max dose. Recursive 
partioning analysis (RPA) was performed to define optimal cut-
points for independent variables. Sensitivity and specificity were 
calculated based on these parameters. Univariable regression 
analysis was used to identify significant predictors of breath hold 
end points. Statistical analyses were performed using SAS (v.9.4) 
with two-sided statistical testing at the 0.05 significance level. 
Results: The median patient age was 53 years and all underwent 
breast-conserving surgery. The MHD was 2.3 Gy (± 0.8) and mean 
V50% was 10.4 cc (± 9.7). RPA determined 73mm as the optimal 
cut-off for HeartContact, 13 mm for Arch4 and 60 mm for Arch5, 
respectively. When considering MHD ≥ 1.7 Gy to predict for BH-
RT, HeartContact sensitivity and specificity were 77% and 90%; 
with Arch4 yielding 80% and 90%, respectively. In the case of 
V50% ≥ 10 cc to predict for BH-RT, HeartContact sensitivity and 
specificity were 87% and 55%; Arch4 yielded values of 100% and 
63% respectively. Arch4 was more sensitive and specific in 
predicting BH-RT than Arch5. On univariable linear regression 
analysis, Heartcontact and Arch4 were found to be statistical 
significant predictors of MHD, V50% and LAD Max dose (p < 0.05). 
Receiver operating curves demonstrated that Arch4 was the most 
accurate predictor of high cardiac dose (MHD ≥ 1.7 Gy and V50% 
≥ 10 mL). 
Conclusions: Our proposed variable, Arch4 holds promise as a 
practical and accurate predictor of high heart dose and the need 
for BH-RT for left-sided breast cancer patients. An external 
validation study is planned to confirm the diagnostic 
performance of our novel variable. 
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Purpose: Despite possessing similar clinicopathological features, 
some PCa patients treated with RP are at high-risk of developing 
local and/or distant recurrence and dying of their cancer, 
whereas many others will have clinically insignificant disease and 
will not benefit from post-operative radiotherapy. A minimally 
invasive diagnostic assay is required to stratify these patients, 
monitor disease progression and response to treatment, 
ultimately improving patient care. Extracellular miRNAs 
embedded in circulating exosomes have sparked much interest 
as potential non-invasive biomarkers for PCa.  
Methods and Materials: Patients who had RP and were referred 
for post-operative radiotherapy were prospectively recruited 
and patient, tumour and treatment factors were abstracted and 
analyzed. Serum exosomes were isolated for extraction of 
miRNAs, and comparative profiling of miRNAs was performed 
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using the NanoString platform. Patients were classified into low- 
versus high-risk groups based on pathological stage (≤ T2 versus 
≥ T3), Gleason Score (GS) (≤ 7 versus ≥ 8), post-operative PSA 
level (≤0.2 versus > 0.2), margin status (positive versus negative) 
and nodal status (positive versus negative). 
Results: Seventy patients were recruited prospectively from 
2015 to 2016 (median age = 64.5 years; range 48-77), and 30 
patients were used as a discovery cohort. Five hundred and 
eighty-eight miRNAs were differentially expressed in serum 
exosomes (301 overexpressed and 287 underexpressed). Of 
these, three miRNAs (miR-122, miR-4421, and miR-92a) and 2 
miRNAs (miR-145 and miR-630) were significantly overexpressed 
and underexpressed (> 2 fold difference, p < 0.05) in patients 
with high pathological stage and GS, respectively. miR-630 was 
found to be the only miRNA significantly downregulated in 
patients harboring all three high-risk features of GS, pathological 
stage and post-operative PSA. Pathway analysis was performed 
and indicated that these differentially expressed miRNAs were 
highly related to PCa carcinogenesis, progression, and 
angiogenesis. Preclinical studies were carried out to investigate 
the biological role of selected miRNAs in PCa proliferation, 
invasion and response to radiation and chemotherapy. 
Conclusions: This is the first report to our knowledge, detailing 
the discovery of a unique signature of exosomal miRNA obtained 
from PCa patient sera post-RP, with direct comparison to 
clinicopathological factors. This exosomal miRNA signature will 
be assessed in a validation cohort to assess its predictive value 
for biochemical recurrence post-RP. 
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Purpose: Radiation necrosis occurs in 10-20% of patients who 
undergo stereotactic radiosurgery (SRS) for brain metastases. 
There are currently no established methods for differentiating 
tumour progression from radionecrosis, and the temporal 
evolution and pathophysiology of vascular changes after high 
dose radiation is poorly understood. Intravoxel incoherent 
motion (IVIM) is a method using MRI-based diffusion-weighted 
imaging (DWI) to assess regional perfusion without intravenous 
contrast. IVIM may help in monitoring the evolution of vascular 
damage and its relationship to tumour control, progression and 
radionecrosis. This study evaluates the temporal evolution of 
IVIM perfusion fraction in brain metastases treated with SRS. 
Methods and Materials: Seventeen patients with brain 
metastases were prospectively enrolled in an REB-approved 
study and underwent MRI scans (including DWI with six b-values) 
at baseline, one week, and one month post-SRS, and were 
subsequently followed with MRI surveillance scans every three 
months. The perfusion fraction (f) was calculated using linear 
fitting. A region of interest was defined by contouring the 
metastases on the post-gadolinium T1-weighted images. The 
mean f and apparent diffusion coefficient (ADC) were calculated 
for each metastasis. Hemorrhagic metastases were excluded due 
to artifacts in associated DWI voxels. 
Results: The primary site of disease was lung (n = 7), breast (n = 
6), rectal (n = 2) and melanoma (n = 2, excluded due to 
hemorrhage). Four patients were lost to follow up. A total of nine 
patients with 10 metastases were included in the final analysis 
with a median follow up of six months. Of the 10 brain 
metastases analyzed, seven exhibited regression with an average 
volume decrease of 81%. The three remaining lesions showed 
early regression followed by progressive enhancement on T1-
weighted images deemed to be consistent with radionecrosis, 
with an average volume increase of 68%. For the lesions that 
responded to SRS, the baseline perfusion fraction (average = 
9.2%) increased slightly at one week post-SRS (average = 9.7%) 
and slightly further at one month (average = 10.9%). For the 
lesions that later developed necrosis, the baseline f (average = 
9.2%) decreased at one week (average = 7.3%) then rebounded 
back to near baseline at one month (average = 8.8%). There was 
a statistically significant difference in the change in f from 
baseline to one week between two groups (average change for 
responders = +6.4%, for necrosis = -19.4%, p = 0.047). There were 
no trends in differences in ADC between the two groups at any 
time point. 
Conclusions: IVIM perfusion fraction may identify brain 
metastases that go on to develop radionecrosis after SRS. An 
early decrease in f could signify a higher degree of SRS-induced 
vascular damage leading to late necrosis. A retrospective 
analysis of an additional 60 patients is currently underway to 
further evaluate the utility of IVIM perfusion fraction. 
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Purpose: The purpose of this study was to evaluate clinical and 
pathologic factors associated with survival in patients with oral 
cavity squamous cell carcinoma (OCSCC), and to compare the 
prognostic performance of clinicopathological models against 
the routinely used TNM staging. 
Methods and Materials: All patients diagnosed with OCSCC 
between 2001-2009 and treated with surgical resection at a 
tertiary referral head and neck surgery department within a 
university centre in Brazil, were identified. Data were 
prospectively collected from hospital charts, tumour registry 
files, and patient interviews. The impact of clinical and 
pathologic risk factors on overall survival (OS) of patients with 
OCSCC was evaluated using the Kaplan-Meier method and log-
rank tests. Factors associated with OS were investigated with 
multivariable Cox models. Results were considered statistically 
significant at p-value < 0.05. Model fit was evaluated using the 
Akaike Information Criterion (AIC). 
Results: A total of 243 patients with OCSCC were identified, 
including 26.8% women and 73.2% men, with a mean age at 
diagnosis of 60.4 (standard error 12.2) years. TNM Stages I, II, 
and III disease comprised 17%, 13%, and 13% of cases 
respectively. Stage IV disease comprised 56% of cases. Median 
follow- up was 28.7 months (interquartile range 11.8–60.0), and 
41.6% died during follow up. Individual factors predictive of all-
cause mortality on univariate analysis included age, TNM Stage, 
pathologic T Stage, pathologic N Stage, tumour size, depth of 
invasion, extracapsular extension, perineural invasion, number 
of symptoms (pain, globus sensation, dysphagia, odynophagia, 
bleeding, otalgia, airway obstruction necessitating 
tracheostomy), and weight loss percentage (p < 0.05). Sex, 
education, tumour differentiation, surgical margin status, 
smoking status, cumulative pack-year smoking history, alcohol 
consumption status, and daily alcohol consumption in grams 
were not correlated with survival. On multivariate analyses, size 
of tumour in centimeters [HR 1.27(1.15 - 1.41)] and age [HR 
1.05(1.03 -1.08)] remained as independent poor prognostic 
factors. There was a trend towards poor prognosis for pathologic 
N Stage [HR 1.29(0.97-1.72)]; margin positivity [HR 1.06(0.56 - 
1.98)]; extracapsular extension [HR 1.41(0.74 - 2.71)]; each 
additional associated symptom [HR 1.12(0.95 - 1.32)]; and per 
pack year increase in tobacco consumption [HR 1.01(1.00 - 
1.01)]. Clinicopathological models based on combinations of 
these seven variables had lower AIC values and were better at 
predicting survival compared to TNM staging. 
Conclusions: Models that take into consideration easily available 
epidemiological, clinical and key pathologic features may 
